Abstract:Background: Enterotoxigenic Escherichia coli (ETEC), defined by their production of heat labile (LT) and/or heat stable (ST) toxins, are major causes of infantile diarrhea in developing countries and of travelers' diarrhea in visitors to the developing world. Despite our understanding of ETEC pathogenesis, no broadly protective ETEC vaccine is available. This is largely a result of the difficulty in inducing immunity to the small ST molecule. Our goal is to develop a broadly protective live attenuated vaccine against ETEC by taking advantage of the recent demonstration (Zhang et al.,2013,PLoSONe 8 (10):e77386) that genetically produced fusions of mutant ST with LT components can induce effective immunity against both toxins. Methods: To achieve this aim, we engineered an attenuated strain of E. coli, which we have developed as a vaccine vector for mucosal antigen delivery, to express immunogenic fusion constructs of LT and mutant ST. Our vaccine vector strain ZCR533, is a derivative of O157:H7 enterohemorrhagic E. coli (EHEC) strain 86-24 attenuated by deleting its genes for Shiga toxin production and truncating its major adhesin, intimin, such that it can no longer adhere intimately, but can still induce anti-intimin antibody. To express LT-ST fusions in immunogenic form in our vector strain, we used restriction-free cloning technology to incorporate them into the passenger domain of an autotransporter protein (EspP) expressed on a medium copy number plasmid. This system is designed to express the toxin antigens in either surface-bound or secreted forms, and to provide effective delivery to the mucosal immune system as we have done for other toxin antigens. Results: The incorporation of the LT-ST fusions into the passenger domain of the EspP autotransporter plasmids was confirmed by PCR and DNA sequencing. Protein expression by ZCR533 containing the autotransporter plasmids was confirmed by SDS-PAGE, and Western blot of whole cell lysates and culture supernates, using poly-clonal antisera to the LT component. Moreover, appropriate expression of the LT-ST fusions on the bacterial surface of ZCR533 was confirmed by immuno-fluorescent staining with the specific antisera. Conclusions: These studies show that immunogenic fusions of LT and mutant ST can be expressed on the surface, and in the culture supernates, of our attenuated E. coli vaccine vector ZCR533 via the EspP autotransporter. Since our recent studies using the similarly-sized Shiga toxin B subunit antigen have indicated the validity of this approach to mucosal immunization against toxin antigens, these studies could lead to the development of broadly protective vaccines directed against both LTand ST-producing ETEC, as well as against attaching/ effacing E. coli strains expressing intimin.

Expression of EspA in Lactococcus lactis NZ9000 and the detection of its immune effect in vivo and vitro

Recombinant Expressing and Protective Immunity of EspA and Es-pB from Enterohemorrhagic E.coli O157∶H7

Intranasal co-administration of recombinant active fragment of Zonula occludens toxin and truncated recombinant EspB triggers potent systemic, mucosal immune responses and reduces span of E. coli O157:H7 fecal shedding in BALB/c mice

High-Level Expression Of Mycobacterium Tuberculosis Protein Espb In E. Coli And Preparation Of Novel Anti-Espb Monoclonal Antibodies

Fusion Expression and Immunogenicity of EHEC EspA-Stx2Al Protein: Implications for the Vaccine Development

Enterohemorrhagic Escherichia Coli Trivalent Recombinant Vaccine Containing EspA, Intimin and Stx2 Induces Strong Humoral Immune Response and Confers Protection in Mice.

Secretory expression of mSTa, LTB and STb fusion protein of ETEC in Lactococcus lactis and the immunogenicity analysis

Construction of Lactococcus lactis expressing secreted and anchored Eimeria tenella 3-1E protein and comparison of protective immunity against homologous challenge

Secretory Expression of K88 (F4) Fimbrial Adhesin FaeG by Recombinant Lactococcus Lactis for Oral Vaccination and Its Protective Immune Response in Mice.

Protective effects of oral immunization with live Lactococcus lactis expressing Eimeria tenella 3-1E protein

Immunization of mice with Lactobacillus casei expressing intimin fragments produces antibodies able to inhibit the adhesion of enteropathogenic Escherichia coli to cultivated epithelial cells.

Development of an Antigen Delivery Platform Using Lactobacillus acidophilus Decorated With Heterologous Proteins: A Sheep in Wolf's Clothing Story

The Expression and Immunological Properties of the Flagella Protein of Burkholderia Pseudomalle Fused with EspA from Enterohemorrhagic Escherichiacoli O157

EspF is Crucial for Citrobacter Rodentium-Induced Tight Junction Disruption and Lethality in Immunocompromised Animals

Passive Protection of Mice Pups Through Oral or Intranasal Immunization of Dams with Recombinant Lactobacillus Casei Vaccine Against ETEC F41.

Mo1948 Toward a Broadly Protective Vaccine Against Enterotoxigenic E.coli (ETEC) Infections

EspA is a Novel Fusion Partner for Expression of Foreign Proteins in Escherichia Coli

Construction and characterization of EHEC 0157△ler/stx(pBR322::stx 1/2B::eae)

Immunogenicity and Protective Efficacy of Orally or Intranasally Administered Recombinant Lactobacillus Casei Expressing ETEC K99

Oral Delivery of Novel Recombinant Lactobacillus Elicit High Protection Against Staphylococcus Aureus Pulmonary and Skin Infections

In vivo characterization of the immune response towards the pathogenic Escherichia coli antigen SslE and modulation of the intestinal microbiota